Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China

CONCLUSIONS: Sin+Chemo is a cost-effective first-line treatment option for advanced HER2-negative GC/GEJC in China.CLINICAL TRIAL REGISTRATION: ORIENT-16, www.clinicaltrials.gov, identifier is NCT03745170.PMID:38594905 | DOI:10.1080/14737167.2024.2341859
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Authors: Source Type: research